OCUP

Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR)

Cash Balance of $40 Million Expected to Fund Operations into 2025

Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire

Common Share Purchase Agreement with Lincoln Park Capital Fund, LLC providing up to $50 million in committed financing over 30 months

FARMINGTON HILLS, Mich., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Key Anticipated Future Milestones

APX3330: End-of-Phase 2 (EOP2) meeting scheduled with FDA to confirm Phase 3 regulatory path for oral APX3330 in DR (Q4 2023)
Nyxol: PDUFA date for Nyxol in RM (September 28, 2023). FDA approval in RM would trigger a $10 million milestone payment to Ocuphire
Nyxol: Topline results from VEGA-2 Phase 3 pivotal trial of Nyxol in Presbyopia (Q4 2023)

Recent Business Highlights

Clinical and Regulatory Updates

In July 2023, Ocuphire confirmed an End-of-Phase 2 meeting with the FDA, scheduled for the fourth quarter of 2023. On the strength of the efficacy and safety data from the ZETA-1 Phase 2 trial of APX3330, and upon agreement with the FDA following the End-of-Phase 2 meeting, Ocuphire plans to pursue binocular 3-step or more worsening (prevention of progression) of diabetic retinopathy severity score (DRSS) as the potential registration primary endpoint.

Corporate

Key Anticipated Future Milestones

APX3330: End-of-Phase 2 (EOP2) meeting scheduled with FDA to confirm Phase 3 regulatory path for oral APX3330 in DR (Q4 2023)
Nyxol: PDUFA date for Nyxol in RM (September 28, 2023). FDA approval in RM would trigger a $10 million milestone payment to Ocuphire
Nyxol: Topline results from VEGA-2 Phase 3 pivotal trial of Nyxol in Presbyopia (Q4 2023)

Recent Business Highlights

Clinical and Regulatory Updates

In July 2023, Ocuphire confirmed an End-of-Phase 2 meeting with the FDA, scheduled for the fourth quarter of 2023. On the strength of the efficacy and safety data from the ZETA-1 Phase 2 trial of APX3330, and upon agreement with the FDA following the End-of-Phase 2 meeting, Ocuphire plans to pursue binocular 3-step or more worsening (prevention of progression) of diabetic retinopathy severity score (DRSS) as the potential registration primary endpoint.

Corporate

Key Anticipated Future Milestones

APX3330: End-of-Phase 2 (EOP2) meeting scheduled with FDA to confirm Phase 3 regulatory path for oral APX3330 in DR (Q4 2023)
Nyxol: PDUFA date for Nyxol in RM (September 28, 2023). FDA approval in RM would trigger a $10 million milestone payment to Ocuphire
Nyxol: Topline results from VEGA-2 Phase 3 pivotal trial of Nyxol in Presbyopia (Q4 2023)

Recent Business Highlights

Clinical and Regulatory Updates

In July 2023, Ocuphire confirmed an End-of-Phase 2 meeting with the FDA, scheduled for the fourth quarter of 2023. On the strength of the efficacy and safety data from the ZETA-1 Phase 2 trial of APX3330, and upon agreement with the FDA following the End-of-Phase 2 meeting, Ocuphire plans to pursue binocular 3-step or more worsening (prevention of progression) of diabetic retinopathy severity score (DRSS) as the potential registration primary endpoint.

Corporate

Bought another 20k shares holding 40k …I can wait, no rush

$OCUP break 6 and we get a banger to 10

Watch out for the fake bulls … this is ready for a big run not a pump/dump bs

Let’s fire away and fuck some short pigs

Premarket banger

Let’s get 5 after hours and destroy the shorts thanksgiving